Congratulations to Micropep Technologies, a Sofinnova Partners Industrial Biotech portfolio company, on its Series B financing and launch of its proprietary discovery platform, Krisalix. Sofinnova was Micropep’s seed investor in 2018. Throughout the years we’ve supported the company in its efforts to revolutionize agriculture sustainability. This new funding round will enable Micropep to accelerate its global go-to-market strategy, and expand the capabilities of its Krisalix platform, enabling rapid identification of the most promising new peptides for crop protection. Learn more: https://hubs.ly/Q02HXxBb0 Guillaume Baxter, Denis Lucquin, Joško Bobanović, Mary McCarthy, Michael Krel, Anna Belousova, Mariam Cherifi, Gabriela Sachet #impactinvesting #agbiotech #SeriesB
Sofinnova Partners
Services financiers
Paris, Ile-de-France 26 910 abonnés
Sofinnova Partners is a leading European VC firm in life sciences, specializing in healthcare and sustainability.
À propos
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: www.sofinnovapartners.com
- Site web
-
http://sofinnovapartners.com/
Lien externe pour Sofinnova Partners
- Secteur
- Services financiers
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Ile-de-France
- Type
- Partenariat
- Fondée en
- 1972
- Domaines
- Pharmaceutical / biotech, Medical devices, Industrial Biotechnology, Sustainability, Biopharma, Medtech, Venture Capital, Private Equity, Biotech et Biotechnology
Lieux
-
Principal
7-11, Boulevard Haussmann
75009 Paris, Ile-de-France, FR
-
1 Pancras Square
N1C 4AG King's Cross, London, GB
-
Via Borgogna, 5
20122 Milan, Lombardy, IT
Employés chez Sofinnova Partners
Nouvelles
-
Congratulations to deepc, a Sofinnova Partners portfolio company, on the close of its financing round. We’ve been lead investors in deepc since the first tranche of their Series A round. deepc is the company behind deepcOS, the leading AI operating system for radiologists and enterprise clinical organizations. The capital raised will be used to continue deepc's international expansion, as well as further enhance its industry-leading operating system. Learn more: https://hubs.ly/Q02HVVD00 Simon Turner Edward Kliphuis Javier Nunez-Vicandi Aishwarya Parthasarathy #digitalmedicine #ai
-
-
Congratulations to ELICIT PLANT a Sofinnova Partners Industrial Biotech portfolio company, on its partnership with Bayer | Crop Science France. Elicit Plant is a cutting-edge AgTech company addressing the impacts climate change is having on major broad acre crops around the word. Its products can reduce water consumption by as much as 20%. The partnership between Elicit Plant and Bayer is aimed at accelerating maize resilience in France. From October 1, 2024, Bayer will become the exclusive distributor in France of Elicit Plant's Best-a and EliZea products, which specifically target water stress issues. Learn more: https://hubs.ly/Q02Hqxnw0 Michael Krel, Mary McCarthy, Guillaume Baxter, Joško Bobanović, Anna Belousova, Mariam Cherifi, and Gabriela Sachet #agtech #sustainibility #sustainableagriculture
-
-
Congratulations to Asceneuron SA, a Sofinnova Partners portfolio company, on its oversubscribed Series C financing of $100M. Asceneuron is a clinical stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease. The recently raised capital will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s Disease. In 2015, Sofinnova Partners led the Series A funding round. We are proud to have attracted new investors for the Series C, including Novo Holdings which led this round. Additionally, EQT Group Life Sciences Dementia Fund, OrbiMed and SR One Capital Management joined as investors, further validating the potential of the platform and our initial investment thesis. Learn more: https://hubs.ly/Q02GHKRH0 Henrijette Richter, Barbara A., Ryan S., Naveed Siddiqi, Hakan Goker, Philip Scheltens, Dina Chaya, Amit Shah #neurodegeneration #fundraising #biotech
-
-
In March, we announced the acquisition of Sofinnova Partners portfolio company Amolyt Pharma by AstraZeneca for up to $1.05 billion. The deal has now officially closed, and we were delighted to sit down with Thierry Abribat, CEO of Amolyt, to get the back story on: • Why he went for a third win after already having two successes under his belt • The qualities of a successful entrepreneur • The French biotech ecosystem • His advice for the next generation of biotech entrepreneurs. Read our CEO Spotlight on Thierry Abribat to learn more: https://hubs.ly/Q02GwZ110 Cédric Moreau #financing #acquisition #biotech #raredisease
-
-
Congratulations to Bioptimus, a Sofinnova Partners portfolio company, on the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology, less than five months after the company’s launch. Bioptimus is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Sofinnova led the French startup $35M seed round in February. Trained on several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices, H-optimus-0 boasts an impressive 1.1 billion parameters and sets a new benchmark for state-of-the-art performance in several critical medical diagnostic tasks, from identifying cancerous cells to detecting genetic abnormalities in the tumor. Learn more: https://lnkd.in/dp8ErEue Edward Kliphuis, Simon Turner, Javier Nunez-Vicandi, Aishwarya Parthasarathy, Rodolphe Jenatton, and Jean-Philippe Vert #digitalmedicine #AI #pathology
🚀 Less than five months after our launch, we’re excited to announce the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology! With 1.1 billion parameters, H-optimus-0 is trained on a proprietary dataset of several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices. This sets a new benchmark for state-of-the-art performance in several critical medical diagnostic tasks, from identifying cancerous cells to detecting genetic abnormalities in the tumor. You can access the model, detailed documentation, and research findings on our GitHub repository: https://lnkd.in/gnpxw3wT Read our press release: https://lnkd.in/gPzr47qN
-
Edward Kliphuis, Partner in our Digital Medicine strategy, discussed the transformational convergence of computation and healthcare on the Nothing Ventured podcast, with host Aarish Shah. Tune into to discover how merging data and computation is revolutionizing healthcare, addressing global challenges, and emphasizing the importance of trust and accurate information. Let us know what you think will shape the future of healthcare. 🤔💡 - YouTube: https://lnkd.in/dMRcZE7X - Spotify: https://lnkd.in/duv6kK84 - Apple: https://lnkd.in/dbUnJrQn #podcast #futureofhealth #healthcareinnovation
𝗪𝗵𝘆 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲 𝗼𝗳 𝗰𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻𝗮𝗹 In this week's epsiode of Nothing Ventured, Aarish sat down with Edward Kliphuis, Partner at Sofinnova Partners, a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Prior to joining Sofinnova Partners, spent close to a decade in venture with Amadeus Capital Partners and M Ventures . Our top takes: 1️⃣ 𝗖𝗼𝗻𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲 𝗼𝗳 𝗗𝗮𝘁𝗮 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻: Edward highlighted the significance of the convergence of data and computation in healthcare. Large biology models, akin to large language models, are revolutionising our understanding of biology. By capturing individual variability and isolating cause and effect, we are moving towards personalized and tailored medicine. 2️⃣ 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: We discussed the challenges faced by healthcare systems globally, including rising costs, demographic changes, and a shortage of practitioners. Edward highlighted the need for innovation to address these systemic issues and ensure accessible and affordable healthcare for all. 3️⃣ 𝗧𝗿𝘂𝘀𝘁 𝗮𝗻𝗱 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: The conversation also touched upon the importance of trust and information in healthcare. With the proliferation of information and misinformation, coupled with the rapid pace of innovation, maintaining trust and delivering accurate information to patients is crucial for the future of healthcare. They also talked about: 🔎 Life sciences through the lens of three strategies - existing tech through new channels, new tech through existing channels and new tech through a new channel. 🔬 Taking healthcare to the individual level. 🦠 Large biology models as a parallel to large language models. Rate and subscribe wherever you get your podcasts ⭐️ YouTube: https://lnkd.in/dMRcZE7X Spotify: https://lnkd.in/duv6kK84 Apple: https://lnkd.in/dbUnJrQn
-
Congratulations to Endoron Medical, a Sofinnova Partners portfolio company, on its series A financing. Endoron is a pioneering medtech company specializing in innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms. The recently raised capital will accelerate the clinical validation of Endoron’s flagship product, the catheter-based EndoStapling solution Aortoseal, as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS). Learn more: https://hubs.ly/Q02FN6yH0 Cécile Dupont Redon, Ronit Harpaz #medtech #endovascular
-
-
Congratulations to Myricx Bio, a Sofinnova Partners portfolio company, on its £90m ($115m) series A financing. We had the privilege of backing the company in 2020 as founding investors and this achievement strengthens our conviction and our commitment to supporting Robin Carr and the team. The newly secured funds will be used to build out their proprietary N-Myristoyltransferase inhibitor (NMTi) ADC payload platform and to advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. We are thrilled to continue being part of this extraordinary journey as MyricxBio pioneers a completely novel class of ADCs, harnessing the potential of NMTi for the treatment of cancer. Learn more: https://hubs.ly/Q02FxJrv0 Maina Bhaman #ADCs #CancerTreatment #SeriesA
-
-
We are committed to incorporating ESG pillars into our investment decisions and engaging with our portfolio companies to enhance their overall environmental, social, and governance impact. Achieving sustainable growth and meaningful outcomes alongside financial performance has always been Sofinnova Partners' credo. We've dedicated years to refining a concrete framework that embodies this ethos. By embedding ESG practices in our investments, we support our portfolio companies in developing solutions that positively impact people and the planet, ensuring that each step in our ESG strategy leads to tangible progress. 🌿 Learn more in our latest report: https://hubs.ly/Q02Fqy4t0 Robert Carroll, Sarah Lafaye #ESG #SustainableInvesting #ImpactInvesting #ResponsibleInvestment #CorporateResponsibility
-